- Home
- MTNB vs IMRN Comparison
MTNB vs IMRN Comparison
Compare MTNB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- IMRN
- Stock Information
- Founded
- MTNB 2013
- IMRN 1994
- Country
- MTNB United States
- IMRN Australia
- Employees
- MTNB N/A
- IMRN N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- IMRN Health Care
- Exchange
- MTNB Nasdaq
- IMRN Nasdaq
- Market Cap
- MTNB 10.8M
- IMRN 9.2M
- IPO Year
- MTNB N/A
- IMRN N/A
- Fundamental
- Price
- MTNB $1.57
- IMRN $2.14
- Analyst Decision
- MTNB Hold
- IMRN
- Analyst Count
- MTNB 1
- IMRN 0
- Target Price
- MTNB N/A
- IMRN N/A
- AVG Volume (30 Days)
- MTNB 38.3K
- IMRN 94.0K
- Earning Date
- MTNB 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- MTNB N/A
- IMRN N/A
- EPS Growth
- MTNB N/A
- IMRN N/A
- EPS
- MTNB N/A
- IMRN N/A
- Revenue
- MTNB N/A
- IMRN $4,777,422.00
- Revenue This Year
- MTNB N/A
- IMRN N/A
- Revenue Next Year
- MTNB N/A
- IMRN N/A
- P/E Ratio
- MTNB N/A
- IMRN N/A
- Revenue Growth
- MTNB N/A
- IMRN 48.63
- 52 Week Low
- MTNB $0.47
- IMRN $1.50
- 52 Week High
- MTNB $3.76
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- MTNB 38.19
- IMRN 54.36
- Support Level
- MTNB $1.82
- IMRN $2.06
- Resistance Level
- MTNB $1.93
- IMRN $2.35
- Average True Range (ATR)
- MTNB 0.13
- IMRN 0.14
- MACD
- MTNB -0.04
- IMRN -0.00
- Stochastic Oscillator
- MTNB 6.82
- IMRN 40.00
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.